AIDS drugs, tests are economical in poor countries
The World Health Organization's Commission on Macroeconomics and Health has established reasonable-cost standards for extending a life. Medical expenses that come in at less than per-capita GDP per year are considered „very cost-effective.” A therapy that costs less than three times that level is still considered „cost-effective.” Three times per capita GDP in the Ivory Coast is $2,124. Basing treatment decisions on a gauge of white blood cells that indicates the strength of the immune system, called a CD4 test, added almost three more years to a patient's life, on average. The test raised the total cost per person in Ivory Coast to $1,180, still economically worthwhile under the WHO standards, Freedberg said. „This simple blood test, even though it includes added costs, allows you to get the most benefit from the medicines,” he said.
CD4 cells, also known as T-helper cells, support the immune system. As HIV advances in the body, the number of CD4 cells decreases. In the absence of these immune-system defenders, potentially deadly infections such as pneumonia, Kaposi's sarcoma and tuberculosis may take hold. Treatment with drugs can reverse the decline of CD4 cells, allowing the body to stave off infections again. The CD4 test is useful because it tells doctors when the immune system has declined to a point that it will have trouble fighting off the HIV-related infections, and that it's time to start prescribing the medicines, Freedberg said. Without the CD4 test, patients don't get the antiretrovirals until after they get an infection that signals a weakened immune system. In African countries, many patients don't survive the first infection, he said. „We found the therapy works well without the lab tests, but it works much better if you do include the tests,” Freedberg said. „And it's also cost-effective to do the tests in poor countries. That is quite controversial.” (Bloomberg)
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.